SCHEMBL2208515

SCHEMBL2208515

CNC(=O)CCCOc1cccc(CCCN)c1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.52
▸ CNR2 P34972 1/20 0.52
▸ HPGD P15428 2/20 0.51
▸ HDAC1 Q13547 1/20 0.50
▸ HDAC6 Q9UBN7 1/20 0.50
▸ CYP2D6 P10635 4/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.47
▸ PPARG P37231 1/20 0.45
▸ PPARA Q07869 1/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ MTNR1A P48039 1/20 0.44
▸ MTNR1B P49286 1/20 0.44
▸ ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29818817 1.00 CNR1 (0.52) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL612170 0.91 CNR2 (0.56) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL27439136 0.88 CNR1 (0.61) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL19291537 0.87 HPGD (0.54) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL13959276 0.87 FFAR1 (0.51) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL4569074 0.85 PPARA (0.48) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL2206370 0.85 SMN1; SMN2 (0.52) HPGDSMN1; SMN2PDK2
SCHEMBL2208586 0.85 PPARG (0.47) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL29818702 0.85 PPARG (0.47) CNR1CNR2HPGDHDAC1HDAC6
SCHEMBL29818936 0.85 SMN1; SMN2 (0.52) HPGDSMN1; SMN2PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 — — US disclosed
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 — — US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 — — US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 — — US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 — — US disclosed
US-11446261-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2022-09-20 — — US disclosed
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2021-03-18 — — US disclosed
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2021-03-18 — — US disclosed
US-10639286-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2020-05-05 — — US disclosed
US-10639286-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2020-05-05 — — US disclosed
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-17 — — US disclosed
US-7982071-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2011-07-19 — — US disclosed
US-7982071-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2011-07-19 — — US disclosed
US-7982071-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2011-07-19 — — US disclosed
US-20090326074-A1 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2009-12-31 — — US disclosed
US-20090326074-A1 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2009-12-31 — — US disclosed
US-20090326074-A1 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2009-12-31 — — US disclosed
EP-2091955-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT Acucela, Inc. (US) 2009-08-26 — — EP disclosed
WO-2009045479-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2009-04-09 — — WO disclosed
WO-2009045479-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2009-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029708-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER CNR1 2237/4885CNR2 2271/4885HPGD 99/4885
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER CNR1 2237/4885CNR2 2271/4885HPGD 99/4885
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER CNR1 2237/4885CNR2 2271/4885HPGD 99/4885
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER CNR1 2205/4885CNR2 2231/4885HPGD 110/4885
US-11446261-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER CNR1 2237/4885CNR2 2271/4885HPGD 99/4885
US-20090326074-A1 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER CNR1 2237/4885CNR2 2271/4885HPGD 99/4885
US-10639286-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER CNR1 2237/4885CNR2 2271/4885HPGD 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback